Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $87,685 | $84,819 | $65,267 | $34,897 |
| % Growth | 3.4% | 30% | 87% | – |
| Cost of Goods Sold | $15,251 | $11,416 | $7,567 | $2,514 |
| Gross Profit | $72,434 | $73,403 | $57,700 | $32,383 |
| % Margin | 82.6% | 86.5% | 88.4% | 92.8% |
| R&D Expenses | $48,990 | $54,219 | $91,572 | $93,245 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $54,645 | $44,856 | $60,939 | $54,571 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $103,635 | $99,075 | $152,511 | $147,816 |
| Operating Income | -$31,201 | -$25,672 | -$94,811 | -$115,433 |
| % Margin | -35.6% | -30.3% | -145.3% | -330.8% |
| Other Income/Exp. Net | $1,389 | $4,806 | -$757 | $60,158 |
| Pre-Tax Income | -$29,812 | -$20,866 | -$95,568 | -$55,275 |
| Tax Expense | -$146 | $561 | $0 | $0 |
| Net Income | -$29,666 | -$21,427 | -$95,568 | -$55,275 |
| % Margin | -33.8% | -25.3% | -146.4% | -158.4% |
| EPS | -0.67 | -0.49 | -2.2 | -1.28 |
| % Growth | -36.7% | 77.7% | -71.9% | – |
| EPS Diluted | -0.67 | -0.49 | -2.2 | -1.28 |
| Weighted Avg Shares Out | 44,329 | 43,645 | 43,704 | 43,182 |
| Weighted Avg Shares Out Dil | 44,329 | 43,645 | 43,704 | 43,182 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,389 | $4,806 | $0 | $0 |
| Interest Expense | $0 | $0 | $757 | $1,852 |
| Depreciation & Amortization | $535 | $735 | $839 | $782 |
| EBITDA | -$30,666 | -$24,937 | -$94,729 | -$54,493 |
| % Margin | -35% | -29.4% | -145.1% | -156.2% |